CClinicalTrials.gg
Sign In
RecruitingNCT06650514OsteomycUpdated Jan 10, 2025

A Phase 2 Pilot Study to Evaluate the Safety and the Anti-Tumour Activity of the Myc Inhibitor OMO-103 Administered Intravenously in Patients With Advanced High-Grade Osteosarcoma

A Phase 2 interventional study of OMO-103 in Osteosarcoma and Osteosarcoma in Children, sponsored by Vall d'Hebron Institute of Oncology. Recruiting at 1 site in Spain. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2025-01-10.

Sponsored by Vall d'Hebron Institute of Oncology · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jun 2026, 4 months ago, but the record still lists the study as recruiting.
  • Started Dec 2024; still recruiting 1 year 9 months later.
Phase
Phase 2
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
12 Years and older
Sex
All
01

Study summary

This is an open-label, unicentric, single-arm Phase 2 pilot study to serve as a proof-of-concept of OMO-103 safety and activity in patients with advanced high-grade osteosarcoma.

Patients will be treated at the RP2D (6.5 mg/kg as a weekly IV infusion) of OMO-103 to estimate anti-tumour activity and further characterise the safety, tolerability, PK, and PD of OMO-103 in advanced high-grade osteosarcoma patients. Ten (10) evaluable patients will be enrolled. At least 30% of patients will be \<18 years old. The first three patients 12-15 years of age will undergo additional safety monitoring.

Patients will be treated until progression by RECIST v1.1 or intolerable toxicity.

02

Conditions studied

  • Osteosarcoma
  • Osteosarcoma in Children

Browse trials for

03

In context

Osteosarcoma

437 studies on the registry are indexed under Osteosarcoma; 116 are open to participants now.

This study's planned enrollment of 10 is below the median of 42 across 325 interventional studies indexed under Osteosarcoma.

Browse Osteosarcoma studies →

Lead sponsor

Vall d'Hebron Institute of Oncology is the lead sponsor of 21 studies on the registry; 14 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Provision of signed and dated informed consent form.
  2. Age ≥12 years at time of informed consent.
  3. Histologically proven, advanced high-grade osteosarcoma not suitable for local treatments with curative intent
  4. Confirmed disease progression by radiological report to at least one line of standard chemotherapy containing cisplatin and anthracycline, and no more than 2 previous lines.

  5. Measurable disease as per RECIST v1.1 criteria and documented by CT/MRI (Appendix 1 - RECIST Response Criteria). NOTE: Lesions to be used as measurable disease for the purpose of response assessment must either:

    1. not reside in a field that has been subjected to prior radiotherapy, or
    2. have demonstrated clear evidence of radiographic progression since the completion of prior radiotherapy and prior to study enrolment.

  6. Provision of a newly obtained tumour biopsy (either from the primary tumour or from metastases) during screening and on-treatment from all patients >16 years of age. Notes:

    • The identified lesion to be biopsied should not have been previously irradiated and should not be the only lesion being used as a measurable-disease target lesion for objective response assessment. Patients must have tumour lesions that can be accessible for biopsy with acceptable clinical risk in the judgement of the Investigator.
    • In case a patient has had a tumour biopsy in the previous 6 months and a paraffin block is available, a new biopsy does not need to be done at Screening (if they have received no treatment after biopsy).
  7. Documented progression on or following the last line of therapy.
  8. ECOG performance status 0-2 (Appendix 2 - Performance Status Criteria).
  9. Life expectancy of ≥ 12 weeks as estimated by the treating physician.
  10. Resolution of all acute, reversible toxic effects of prior therapy or surgical procedure to Grade ≤1 (except alopecia and peripheral neuropathy to Grade ≤2).
  11. Adequate organ function.
  12. If not postmenopausal or surgically sterile, female patients and female sexual partners of male patients must be willing to use at least one highly effective method of birth control (hormonal contraception, IUD, abstinence, condom) for at least a menstrual cycle before and for 3 months after last study drug administration.

Exclusion criteria

Exclusion Criteria:

  1. Treatment with systemic anti-cancer therapy within three weeks prior to study drug administration for chemotherapy and 5 half-lives for targeted therapies.
  2. Radiation therapy within four weeks prior to study entry. Localised palliative radiotherapy to nontarget lesions is allowed
  3. Low-grade osteosarcoma, parosteal, or periosteal osteosarcoma.
  4. Prior history of other malignancies other than osteosarcoma (except for basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix) unless the patient has been free of the disease for at least 2 years.
  5. Non-malignant systemic disease including cerebrovascular accident, unstable angina pectoris, unstable atrial fibrillation, unstable cardiac arrhythmia, myocardial infarction in the last six months, New York Heart Association (NYHA) Class III or IV heart failure (Appendix 5 - New York Heart Association Criteria).
  6. Patients with active uncontrolled infection or known to be serologically positive for human immunodeficiency virus (HIV), hepatitis B (except after vaccination) or hepatitis C infection. Investigators may test as per their discretion.
  7. Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the Investigator, would make the patient inappropriate for entry into this study.
  8. Patients with symptomatic or unstable central nervous system primary tumour or metastases and/or sarcomatous meningitis
  9. Live vaccine in the last four weeks.
  10. Current participation in another interventional therapeutic trial.
  11. Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study.
  12. Knowledge of any other disease or medication that may interfere with study treatment.
  13. Patients with known allergies or hypersensitivity reactions to the active substance or to any of its excipients
  14. Patient unable to comply with the study protocol owing to psychological, social (lack of social support or social exclusion) or geographical reasons.
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    OMO-103

    OMO-103 administered at the recommended phase 2 dose (6.5 mg/kg as a weekly intravenous infusion in 28-day cycles)

    Drug: OMO-103

Interventions

  • DrugOMO-103

    OMO-103 administered at the recommended phase 2 dose (6.5 mg/kg as a weekly intravenous infusion in 28-day cycles).

06

What researchers measure

Primary outcomes

  1. Preliminary anti-tumour activity of OMO-103 monotherapy in patients with high-grade osteosarcoma

    Progression-free survival rate at 16 weeks (16-week PFS)

    Time frame: 16 weeks from start of treatment

Secondary outcomes

  1. Further evaluate the anti-tumour activity of OMO-103 monotherapy in patients with high-grade osteosarcoma.

    • Objective Response Rate (ORR) is defined as the percentage of patients with a complete response (CR) or a partial response (PR) by Investigator according to RECIST 1.1 in solid tumours.

    Time frame: Until disease progression, unacceptable toxicity, patient request, physician's decision to withdraw treatment, subsequent anticancer therapy, or death whichever occurs first, assessed up to 24 months

  2. Further evaluate the anti-tumour activity of OMO-103 monotherapy in patients with high-grade osteosarcoma.

    • Disease Control Rate (DCR) is defined as the percentage of patients in whom the best overall response is determined as CR, PR, or stable disease (SD) by the Investigator according to RECIST 1.1 in solid tumours.

    Time frame: Until disease progression, unacceptable toxicity, patient request, physician's decision to withdraw treatment, subsequent anticancer therapy, or death whichever occurs first, assessed up to 24 months

  3. Further evaluate the anti-tumour activity of OMO-103 monotherapy in patients with high-grade osteosarcoma.

    • Time to Response (TTR) is defined as the time from start of treatment to the date of first documentation of CR, or PR.

    Time frame: Until disease progression, unacceptable toxicity, patient request, physician's decision to withdraw treatment, subsequent anticancer therapy, or death whichever occurs first, assessed up to 24 months

  4. Further evaluate the anti-tumour activity of OMO-103 monotherapy in patients with high-grade osteosarcoma.

    • Time to Progression (TTP) is defined as the time from start of treatment to the date of first documentation of disease progression.

    Time frame: Until disease progression, unacceptable toxicity, patient request, physician's decision to withdraw treatment, subsequent anticancer therapy, or death whichever occurs first, assessed up to 24 months

  5. Further evaluate the anti-tumour activity of OMO-103 monotherapy in patients with high-grade osteosarcoma.

    • Duration of Response (DOR) refers to the minimum from the time when complete response (CR) or partial response (PR) is first observed to the time of progressed disease (PD)

    Time frame: Until disease progression, unacceptable toxicity, patient request, physician's decision to withdraw treatment, subsequent anticancer therapy, or death whichever occurs first, assessed up to 24 months

  6. Further evaluate the anti-tumour activity of OMO-103 monotherapy in patients with high-grade osteosarcoma.

    • Overall survival (OS) is defined as the time from the date of start of treatment to the date of death due to any cause. Patients without documentation of death at the time of analysis will be censored at the date last known to be alive.

    Time frame: Until patient request or death whichever occurs first, assessed up to 24 months

  7. Safety and tolerability profile of OMO-103 monotherapy in patients with high-grade osteosarcoma.

    Incidence and severity of adverse events (AEs), graded by Common Terminology Criteria for Adverse Events (CTCAE) v5.

    Time frame: Unrtil end of treatment assessed up to 24 months

  8. Assess the benefit/risk ratio associated with OMO-103

    Q-TWiST approach (Quality-adjusted Time Without Symptoms of disease recurrence or Toxicity of treatment)time experiencing toxicity (grade 3/4 AEs) before progression, time without toxicity or symptoms of progression, and time after progression

    Time frame: Until progression assessed up to 24 months

  9. To characterise the pharmacokinetics (PK) of OMO-103 monotherapy in patients with high-grade osteosarcoma (12-15 years of age).

    PK parameters of OMO-103: AUC (Area Under the Curve)

    Time frame: During the first cycle of treatment (4 weeks)

  10. To characterise the pharmacokinetics (PK) of OMO-103 monotherapy in patients with high-grade osteosarcoma (12-15 years of age).

    PK parameters of OMO-103: Cmax (Peak Plasma Concentration)

    Time frame: During the first cycle of treatment (4 weeks)

  11. To characterise the pharmacokinetics (PK) of OMO-103 monotherapy in patients with high-grade osteosarcoma (12-15 years of age).

    PK parameters of OMO-103: tmax (time to peak drug concentration)

    Time frame: During the first cycle of treatment (4 weeks)

  12. To characterise the pharmacokinetics (PK) of OMO-103 monotherapy in patients with high-grade osteosarcoma (12-15 years of age).

    PK parameters of OMO-103: t1/2 (elimination half life)

    Time frame: During the first cycle of treatment (4 weeks)

  13. Evaluate quality of life (QoL) in patients with high-grade osteosarcoma

    For adult patients: Health-related quality of life (HRQoL) measured by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 items (EORTC-C30)

    Time frame: Unitl end of treatment assessed up to 24 months

  14. Evaluate quality of life (QoL) in patients with high-grade osteosarcoma

    For patients between 12 and 17 years of old Health-related quality of life (HRQoL) measured by the Pediatric Quality of Life Inventory (PedsQL)

    Time frame: Unitl end of treatment assessed up to 24 months

07

Study locations

1 of 1 sites recruiting
  • Hospital Universitari Vall d'Hebron
    Barcelona, 08035, Spain
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06650514
Lead sponsor
Vall d'Hebron Institute of Oncology
Collaborators
Peptomyc S.L., Osteosarcoma Institute, Curing Kids' Cancer Foundation, Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center, Oregon Health and Science University, The Morgan Adams Foundation, The Kristen Ann Carr Fund
Responsible party
Sponsor
First posted
Oct 21, 2024
Start date
Dec 27, 2024
Primary completion
Jun 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Jan 10, 2025

Study contacts

Claudia M Valverde
Contact
cvalverde@vhio.net
+34932746085

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Osteosarcoma→

Other studies from this sponsor

Vall d'Hebron Institute of Oncology

Start the discussion